Overview
Lupin Limited is one of India's leading pharmaceutical companies with a global presence across branded and generic medicines, complex formulations, biotechnology products, and active pharmaceutical ingredients. The company operates in more than 100 countries and derives a significant portion of its revenue from regulated markets, including the United States and Europe. Lupin continues to strengthen its global product portfolio through regulatory approvals, new launches, manufacturing expansion, and strategic settlements.
Patent Settlement and Regulatory Approvals Expand Global Presence
Lupin recently entered into a USD 90.00 million settlement agreement with Astellas Pharma to resolve a patent dispute related to the bladder drug Mirabegron. The agreement allows the company to continue marketing its product in the United States while removing legal uncertainty surrounding the product.
The company also continued to strengthen its regulatory pipeline by receiving approval from the European Medicines Agency for the pediatric expansion of NaMuscla. In addition, the U.S. Food and Drug Administration approved Enzalutamide tablets and Ranluspec injection, further expanding Lupin's presence in the regulated pharmaceutical market.
Manufacturing and Product Portfolio Continue to Strengthen
Lupin also received an Establishment Inspection Report from the U.S. FDA for its Ankleshwar manufacturing facility, while its Somerset facility received a Voluntary Action Indicated classification. The company further expanded its product offerings by launching Azilsartan Medoxomil tablets in the United States and introducing Luforbec in Spain through a strategic collaboration. These developments continue to support Lupin's efforts to strengthen its manufacturing capabilities and diversify its global product portfolio.
Financial Performance Reflects Stable Business Momentum
For the quarter ended March 31, 2026, Lupin reported consolidated total income of ₹761,537.00 million. Profit before tax stood at ₹192,800.00 million, while net profit came in at ₹146,867.00 million. Earnings per share for the quarter were reported at ₹31.96, reflecting continued profitability across its diversified pharmaceutical operations.
Lupin Continues to Trade Above Its Medium-Term Trend
From a technical perspective, Lupin continues to trade above its 50-day Simple Moving Average of ₹2,307.33, indicating that the broader medium-term trend remains constructive despite mild intraday weakness. The stock is currently consolidating after a strong upward move toward recent highs around ₹2,423.80. Meanwhile, the 14-day Relative Strength Index stands at 61.72 and remains above its moving average of 59.10, suggesting momentum continues to stay positive without entering deeply overextended territory.
Can Lupin Sustain Its Position Near Recent Highs?
Lupin is currently trading around ₹2,390.50 after witnessing some profit booking from recent highs. Immediate resistance is placed near ₹2,423.80, while a sustained move above this level could keep the recent upward structure intact. On the downside, the 50-day moving average near ₹2,307.33 remains an important reference zone, followed by the recent consolidation region around ₹2,300.00. Market participants are likely to monitor further regulatory approvals, product launches, manufacturing updates, and quarterly earnings for the next directional cues.
Summary
Lupin remains in focus following its USD 90.00 million patent settlement, multiple regulatory approvals, and continued expansion across regulated markets. Alongside steady financial performance and manufacturing developments, the company continues to strengthen its global pharmaceutical footprint. On the technical front, the stock remains above its medium-term trend while consolidating near recent highs.
FAQ
Q: Why is Lupin in focus today?
Lupin is in focus after announcing a USD 90.00 million patent settlement, receiving multiple regulatory approvals, and expanding its product portfolio across key global markets.
Q: What was the patent settlement about?
The company reached a USD 90.00 million settlement with Astellas Pharma related to Mirabegron, allowing it to continue selling the product in the United States.
Q: Which new approvals has Lupin received?
Lupin received EMA approval for the pediatric expansion of NaMuscla and U.S. FDA approvals for Enzalutamide tablets and Ranluspec injection.
Q: How did Lupin perform financially in the latest quarter?
For the quarter ended March 31, 2026, Lupin reported consolidated total income of ₹761,537.00 million and net profit of ₹146,867.00 million.
Q: What does the current technical setup indicate?
The stock continues to trade above its 50-day moving average while consolidating near recent highs, with momentum remaining positive based on the RSI reading.